. Author manuscript; available in PMC: 2014 Jan 31.

Published in final edited form as: Int J Cancer. 2012 Apr 24;131(11):2478–2486. doi: 10.1002/ijc.27541

Table 2.

Crude and adjusted odds ratios (ORs) for the risk of esophageal adenocarcinoma by MMP1 polymorphism in the overall cohort and in GERD vs. GERD-free subsets

Clinical parameter	Total number of cases/controls¹	Crude analysis
		1G/2G vs. 1G/1G		2G/2G vs. 1G/1G
		OR (95% CI)	p value	OR (95% CI)	p value
Overall	309/279	1.41 (0.9–2.1)	0.079	2.05 (1.3–3.3)	0.002
GERD subset	150/62	2.43 (1.2–5.0)	0.016	10.29 (3.9–27.3)	<0.001
GERD-free subset	159/217	1.06 (0.7–1.7)	0.804	0.57 (0.3–1.1)	0.085
		Adjusted analysis ²
		*1G/2G vs. 1G/1G*		*2G/2G vs. 1G/1G*
		OR (95% CI)	p value	OR (95% CI)	p value
Overall	309/279	1.39 (0.9–2.1)	0.097	2.11 (1.3–3.4)	0.002
GERD subset	150/62	2.54 (1.2–5.3)	0.014	10.87 (4.0–29.2)	<0.001
GERD-free subset	159/217	0.99 (0.6–1.6)	0.982	0.55 (0.3-1.1)	0.078

[N/n], where N = number of cases and n = number of controls. Overall: 2G/2G [77/96]; 1G/2G [150/133]; 1G/1G [82/50]; total [309/279]. GERD subset: 2G/2G [21/24]; 1G/2G [66/31]; 1G/1G [63/7]; total [150/62]. GERD-free subset: 2G/2G [56/72]; 1G/2G [84/102]; 1G/1G [19/43]; total [159/217].

Adjusted for age, gender, smoking status, pack-years and adult BMI.